China SFDA Bans Sale And Use Of Ciwujia Injection
October 13, 2008 |
Print
|
Email
| Category: Health
Local media reports that following three deaths in Yunnan province China's Ministry of Health and State Food and Drug Administration have jointly issued an urgent notice to ban the sale and use of Ciwujia injection produced by Heilongjiang Wandashan Pharmaceutical.
According to the notice serious adverse reactions to the Ciwujia injection appeared in six patients after they received the injection and three of them died, according to the notice. The lot numbers of the two batches of Ciwujia injection involved are 2007122721 and 2007121511.
The Ciwujia injection is mainly used for cardiovascular and cerebrovascular disease and liver and gallbladder disease.
The Ministry of Health and the SFDA have sent two workgroups to Yunnan and Heilongjiang for further investigation and medical treatment.
Leave A Comment:
-
Energy & Cleantech
-
Environment
- PepsiCo Opens First Overseas 'Green' Plant In China
- Chinese Official Suggests Abolishing Disposable Wooden Chopsticks
- Retail Markets In China Face Punishment Over Substandard Plastic Bags
- China First Heavy Industries Fined For Infringement Of Environmental Rules
- Energy-saving Lamps For Low-income Households In Shanghai
-
Giving
-
Law & Order
- China Campaigns Against "Cultural Irregularities" On The Internet
- Beijing Sogou Sues Tencent Over Unfair Competition
- Google China Blamed By CCTV For Vulgar Content
- Beijing Will Adopt Real Name Registration For Website Editors And Publishers
- Retail Markets In China Face Punishment Over Substandard Plastic Bags
-
Viewpoints
- Companies Can Help In The March Towards Better Consumer Rights In China
- CSR Review: Companies Have More Opportunities To Develop In China
- How Far Can Chinese Companies Take Corporate Social Responsibility?
- CSR Review: Companies Focus On Sustainability In China During Downturn
- Global Financial Woes May Impact Corporate Social Responsibility In China





























